CombiMatrix Appoints Jeremy M. Jones to Board of Directors

CombiMatrix Appoints Jeremy M. Jones to Board of Directors

Senior Healthcare Services Executive Brings 35 Plus Years Industry Experience
to Board

IRVINE, Calif., Nov. 26, 2012 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing
services for cancer and developmental disorders, today announced that veteran
healthcare services executive Jeremy M. Jones has been appointed to the Board
of Directors, effective immediately. He fills a current vacancy on the Board,
which with this appointment is now made up of six Directors.

Jones brings over 35 years of healthcare industry experience to the
CombiMatrix Board.As a Director, Jones has served on Audit, Compensation, and
Corporate Governance Committees and has a working familiarity with the
Sarbanes-Oxley Act of 2002.During his career he has successfully led
healthcare industry coalition efforts to unify the industry's splintered
message to legislators, while building the largest homecare service provider
in the nation, Apria Healthcare Group Inc., through merger, acquisitions and
increased market dominance.

"We are pleased to welcome Jeremy to our Board.He is a seasoned and well
respected healthcare executive with extensive experience in building and
leading a number of successful healthcare companies," said Mark P. McGowan,
Chairman of the CombiMatrix Board of Directors. "His diverse background,
clinical laboratory and healthcare distribution experience combined with his
large network of industry associates will be valuable resources as CombiMatrix
pursues its strategy to become a world-class commercial laboratory,
specializing in molecular diagnostic services."

Jones is well known for his exemplary track record of providing vision,
expertise and leadership to successful healthcare organizations.Since 2000,
he has been active as a strategic advisor, investor, and Director for
healthcare distribution, home health care, clinical laboratory, disease
management, and professional staffing businesses.

He is currently Chairman of NYSE-traded On Assignment Inc., a leading global
provider of highly skilled, hard-to-find professionals in the life sciences,
healthcare, and technology sectors, and he is on the Advisory Board of
MedidaMetrics, provider of Exactcost Solutions. Jones was an investor in, and
Chairman, of home health service companies, Byram Healthcare Centers Inc, and
Lifecare Solutions, Inc, until their sale in 2008, and 2011. He has also
served on the Board of US Labs, Inc., acquired by Lab Corp in 2005, Byram
Healthcare, acquired by OPG Inc. in 2008 and Cardium Healthcare, acquired by
CenCorp Health in 2006.

Jones has served two terms as Chairman of the Health Industry Distributors
Association and was a Board Member of the National Association of Medical
Equipment Services and founding Chairman of the Home Oxygen Services
Coalition.He received the Dr. Jonas Salk Memorial Mentor in Medicine Award
from the March of Dimes, recognizing him for his proven medical achievements
as well as support of wellness programs aimed at the prevention of birth
defects.

Jones lives with his family in Southern California and holds a bachelor's
degree in business administration from the University of Iowa.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix
Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory
which offers DNA-based testing services to the prenatal, pediatric and
oncology markets.The Company performs genetic testing utilizing Microarray,
FISH, PCR and G-Band Chromosome Analysis.CMDX offers prenatal and pediatric
testing services for the detection of abnormalities of genes at the DNA level
beyond what can be identified through traditional technologies.CMDX was also
the first commercial clinical laboratory in the United States to make
comprehensive DNA-based genomic analysis of solid tumors, including breast,
colon, lung, prostate and brain tumors, available to oncology patients and
medical professionals.Additional information about CMDX is available at
www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995.These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change.All statements, other than
statements of historical fact included in this press release, are
forward-looking statements.Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not limited to,
statements regarding projected results of operations and management's future
business, operational and strategic plans, test menu expansion, services and
reports development and attracting greater prenatal genetic screening
business.These forward-looking statements are not guarantees of future
results and are subject to risks, uncertainties and assumptions that could
cause our actual results to differ materially and adversely from those
expressed in any forward-looking statement.The risks and uncertainties
referred to above include, but are not limited to:our ability to successfully
expand the base of our customers and strategic partners, add to the menu of
our diagnostic tests in both of our primary markets, develop and introduce new
tests and related reports, optimize the reimbursements received for our
testing services, and increase operating margins by improving overall
productivity and expanding sales volumes; our ability to successfully
accelerate sales, allow access to samples earlier in the testing continuum,
steadily increase the size of our customer rosters in both developmental
medicine and oncology; our ability to attract and retain a qualified sales
force; rapid technological change in our markets; changes in demand for our
future products; legislative, regulatory and competitive developments; general
economic conditions; and various other factors.Further information on
potential factors that could affect our financial results is included in our
Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other
filings with the Securities and Exchange Commission.We undertake no
obligation to revise or update publicly any forward-looking statements for any
reason, except as required by law.

CONTACT: Company Contact:
         R. Judd Jessup
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
        
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         len@allencaron.com
        
         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217

CombiMatrix Corporation
 
Press spacebar to pause and continue. Press esc to stop.